Dishman Carbogen Amcis Says Results of Successful Clinical Research Study

Dishman Carbogen Amcis announced the positive results of partnering with Boston University School of Medicine on a clinical research study that reveals a positive response for vitamin D deficiency / insufficiency in patients with COVID-19.

Dishman Carbogen Amcis, a global pharmaceutical industry outsourcing partner, reported positive results from a new clinical research study that showed oral 25-hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency / insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing the percentages of lymphocytes in the blood.

The research was overseen by Tehran University of Medical Sciences and Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis wholly owned subsidiary Carbogen Amcis BV.

The study showed that patients receiving the 25-hydroxy metabolite had a clearly more favorable development of their immunological defense against COVID-19 compared to those given a placebo. Thus, the dosage of the metabolite significantly increased the blood levels as well as the comparative percentage of lymphocytes in the blood, i.e. a reduced neutrophils / blood lymphocytes ratio.

On a consolidated basis, the company’s net profit jumped 51.6% to Rs 11.19 crore on a 4.4% increase in net sales to Rs 458.90 crore in the second quarter of September 2021 compared to second quarter of September 2020.

Shares of Dishman Carbogen Amcis rose 0.88% to Rs 247.45 on BSE. Dishman Carbogen Amcis provides a portfolio of drug development and marketing services to the pharmaceutical and biopharmaceutical industries at all stages of drug development.

Powered by Capital Market – Live News

(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor


Source link

Comments are closed.